JAMES TRAHAN: Open Payments
NPI 1699863019 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$406 in 14 payments from 8 companies in 2025. Trend: 2023 $343 · 2024 $507 · 2025 $406
Food & beverage: $406
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $125 |
| Alkermes, Inc. | 3 | $88 |
| Teva Pharmaceuticals USA, Inc. | 2 | $53 |
| Neurocrine BioSciences, Inc. | 2 | $48 |
| ABBVIE INC. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $14 |
Products named: COBENFY, ARISTADA, AUSTEDO XR, INGREZZA, VRAYLAR, ABILIFY ASIMTUFII, CAPLYTA, Xelstrym.
Industry payments across MO — which companies pay providers there.
